Physician profile
Chad A Parrish
NPI 1992990311
$4,719.70
in general payments reported to CMS, 2019-2025
25 companies · $524 in 2025
The $524 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $530 · 2022: $695 · 2023: $910 · 2024: $2,060 · 2025: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,716 · Travel and Lodging: $778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,716.17 |
| Travel and Lodging | $778.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $2,339.43 | 2022-2025 | Xeomin |
| Abbvie INC. | $928.49 | 2021-2025 | |
| Novo Nordisk INC | $248.91 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $245.55 | 2021-2025 | Airsupra, Breztri |
| Aerin Medical INC. | $150.69 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.39 | 2021-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $98.07 | 2021-2025 | Jardiance, Zepbound, Emgality |
| Organon LLC | $67.95 | 2021-2022 | |
| Abbott Laboratories | $63.38 | 2021-2022 | |
| Pfizer INC. | $57.76 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.20 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $49.62 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $42.82 | 2022 | |
| Medtronic, INC. | $42.81 | 2025 | Minimed 780g, Inceptiv |
| Sunovion Pharmaceuticals INC. | $34.70 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $30.14 | 2025 | Auvelity |
| Organogenesis INC. | $28.29 | 2024 | |
| Almatica Pharma LLC | $27.90 | 2021-2023 | Loreev Xr |
| Boston Scientific Corporation | $23.95 | 2025 | Wavewriter Alpha Prime 16 |
| Optinose US, INC. | $19.65 | 2022 | |
| Genentech USA, INC. | $15.24 | 2021 | |
| Cranial Technologies, INC | $13.91 | 2021 | |
| Eisai INC. | $13.91 | 2021 | |
| Tris Pharma INC | $13.60 | 2021 | |
| Exact Sciences Corporation | $13.34 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Parrish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.